BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for...

Zealand Pharma announces first patient dosed in Phase 2 trial with long-acting GLP-1/glucagon dual agonist in obesity/diabetes Company announcement – No. 38 / 2020 Zealand Pharma announces first patient dosed in Phase 2 trial with long-acting GLP-1/glucagon dual agonist in obesity/diabetes The 410-patient...

PROCESSA PHARMACEUTICALS ANNOUNCES LAST PATIENT ENROLLED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA HANOVER, MD, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...

Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo Hamilton, Bermuda, July 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...

Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...